Drug Approval Signals New Options for Stroke, Heart Attack Survivors in Europe
Heart patients in Europe have something to celebrate. This week, the European Commission approved a groundbreaking new drug, evolocumab, to prevent heart attack and stroke for patients who have already survived a cardiac event. The approval marks the entry of an important new tool for secondary prevention. Evolocumab is a PCSK9 inhibitor, which reduces cardiovascular […]
